Abstract
The proposed stepwise pharmacological treatment of so called “dialysis-resistant” hypertension (DRH), i.e. elevated blood pressure in patients on chronic hemodialysis that is not controlled by ultrafiltration, includes converting enzyme inhibitor Captopril and calcium channel blocker nifedipine as first line drugs (1). The aim of the present study was to compare the acute effects of these drugs in patients with DRH in order to predict the better individual choice.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Similar content being viewed by others
References
Heyka, R.J. and Paganini, E.P. In: Replacement of Renal Function by Dialysis III (Ed. J.F. Maher), Kluwer Academic Publishers Dordrecht/Boston/Lancaster, 1989, pp. 772–787.
Iseki, K., Onoyama, K., Fujimi, S. and Omae, T. Clin. Nephrol. 16: 137–141, 1981.
Moreira, J., Barata, J.D. and Olias, J. Nephron 41: 314–419, 1985.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1991 Springer Science+Business Media Dordrecht
About this chapter
Cite this chapter
Ljutić, D., Rumboldt, Z., Vlašić, F. (1991). First Choice Treatment of Dialysis-Resistant Hypertension: A Crossover Comparison of Single Oral Dose of Captopril and Nifedipine. In: Andreucci, V.E., Dal Canton, A. (eds) New Therapeutic Strategies in Nephrology. Developments in Nephrology, vol 30. Springer, Boston, MA. https://doi.org/10.1007/978-1-4615-3884-4_69
Download citation
DOI: https://doi.org/10.1007/978-1-4615-3884-4_69
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4613-6732-1
Online ISBN: 978-1-4615-3884-4
eBook Packages: Springer Book Archive